Last Updated : December 17, 2022
Details
FilesGeneric Name:
atezolizumab
Project Status:
Complete
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
Hoffmann-La Roche
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0269-000
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Atezolizumab as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II-IIIA (according to AJCC/UICC 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on 50% of tumour cells (TCs) and do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
Atezolizumab as
monotherapy for adjuvant treatment following resection and platinum-based
chemotherapy for patients with non-small cell lung cancer (NSCLC) whose tumours
have PD-L1 expression on ≥ 50% of tumour cells (TCs).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | January 26, 2022 |
| Call for patient/clinician input closed | March 18, 2022 |
| Clarification: - Patient input submission received from Lung Cancer Canada and Lung Health Foundation / The Ontario Lung Association | |
| Submission received | February 24, 2022 |
| Submission accepted | March 10, 2022 |
| Review initiated | March 11, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | May 26, 2022 |
| Deadline for sponsors comments | June 06, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | June 30, 2022 |
| Expert committee meeting (initial) | July 13, 2022 |
| Draft recommendation issued to sponsor | July 26, 2022 |
| Draft recommendation posted for stakeholder feedback | August 04, 2022 |
| End of feedback period | August 18, 2022 |
| Final recommendation issued to sponsor and drug plans | September 01, 2022 |
| Final recommendation posted | September 20, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | September 16, 2022 |
| CADTH review report(s) posted | December 15, 2022 |
Files
Last Updated : December 17, 2022